sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir.
|
indinavir
|
indinavir
|
NONE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s4
|
DDI-DrugBank.d97.s4.p2
|
Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
|
carbamazepine
|
clonazepam
|
MECHANISM
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s5
|
DDI-DrugBank.d333.s5.p5
|
However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.
|
quinolones
|
warfarin
|
EFFECT
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s4
|
DDI-DrugBank.d347.s4.p0
|
Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;
|
Griseofulvin
|
combination hormonal contraceptives
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s23
|
DDI-DrugBank.d485.s23.p2
|
Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.
|
ketoconazole
|
astemizole
|
MECHANISM
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s4
|
DDI-DrugBank.d165.s4.p4
|
Using calcium acetate with digitalis glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.
|
calcium acetate
|
digitalis glycosides
|
EFFECT
|
Calcium Acetate_ddi.xml
|
DDI-DrugBank.d494.s1
|
DDI-DrugBank.d494.s1.p0
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
chloramphenicol
|
para-aminobenzoic acid
|
NONE
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p43
|
Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
|
caffeine
|
caffeine
|
NONE
|
Caffeine_ddi.xml
|
DDI-DrugBank.d89.s3
|
DDI-DrugBank.d89.s3.p3
|
however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.
|
ranitidine
|
ceftibuten
|
MECHANISM
|
Ceftibuten_ddi.xml
|
DDI-DrugBank.d32.s7
|
DDI-DrugBank.d32.s7.p1
|
In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.
|
methylxanthines
|
adenosine
|
ADVISE
|
Adenosine_ddi.xml
|
DDI-DrugBank.d226.s5
|
DDI-DrugBank.d226.s5.p1
|
Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.
|
diltiazem
|
midazolam
|
MECHANISM
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s33
|
DDI-DrugBank.d565.s33.p0
|
conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
|
diethylpropion
|
guanethidine
|
INT
|
Diethylpropion_ddi.xml
|
DDI-DrugBank.d352.s3
|
DDI-DrugBank.d352.s3.p1
|
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
|
hypnotics
|
opioids
|
NONE
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s0
|
DDI-DrugBank.d257.s0.p42
|
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
|
phenytoin
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s30
|
DDI-DrugBank.d124.s30.p6
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
|
epinephrine
|
monoamine oxidase inhibitors
|
EFFECT
|
Lidocaine_ddi.xml
|
DDI-DrugBank.d564.s0
|
DDI-DrugBank.d564.s0.p5
|
Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.
|
thiazides
|
amphetamine
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s5
|
DDI-DrugBank.d236.s5.p2
|
Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
|
benzodiazepine class
|
alcohol
|
EFFECT
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s7
|
DDI-DrugBank.d333.s7.p0
|
Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
|
benzodiazepine class
|
butyrophenone classes of antipsychotic agents
|
EFFECT
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s7
|
DDI-DrugBank.d333.s7.p7
|
Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
|
Erythromycin
|
midazolam
|
MECHANISM
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s6
|
DDI-DrugBank.d397.s6.p1
|
In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.
|
cimetidine
|
tricyclic antidepressant
|
MECHANISM
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s25
|
DDI-DrugBank.d223.s25.p5
|
Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage.
|
Sodium thiosulfate
|
cisplatin
|
EFFECT
|
4038510.xml
|
DDI-MedLine.d130.s2
|
DDI-MedLine.d130.s2.p0
|
Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.
|
ibuprofen
|
furosemide
|
EFFECT
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s9
|
DDI-DrugBank.d415.s9.p3
|
Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
|
metoclopramide
|
metoclopramide
|
NONE
|
Carbidopa_ddi.xml
|
DDI-DrugBank.d47.s7
|
DDI-DrugBank.d47.s7.p1
|
Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.
|
probenecid
|
PIPRACIL
|
MECHANISM
|
Piperacillin_ddi.xml
|
DDI-DrugBank.d462.s5
|
DDI-DrugBank.d462.s5.p3
|
In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.
|
escitalopram
|
escitalopram
|
NONE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s31
|
DDI-DrugBank.d568.s31.p5
|
Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
|
Cisapride
|
sotalol
|
ADVISE
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s14
|
DDI-DrugBank.d237.s14.p3
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
cisapride
|
disopyramide
|
NONE
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p70
|
Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.
|
agents with b-blocking properties
|
monoamine oxidase inhibitors
|
EFFECT
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s3
|
DDI-DrugBank.d269.s3.p1
|
Intravenous ranitidine was shown to double the bioavailability of oral alendronate.
|
ranitidine
|
alendronate
|
MECHANISM
|
Alendronate_ddi.xml
|
DDI-DrugBank.d430.s0
|
DDI-DrugBank.d430.s0.p0
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
contraceptives
|
quinidine
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p69
|
Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.
|
Cimetidine
|
chloroquine
|
MECHANISM
|
Chloroquine_ddi.xml
|
DDI-DrugBank.d429.s2
|
DDI-DrugBank.d429.s2.p2
|
However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.
|
leucovorin
|
methotrexate
|
EFFECT
|
Leucovorin_ddi.xml
|
DDI-DrugBank.d151.s2
|
DDI-DrugBank.d151.s2.p0
|
Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients.
|
Beta-blockers
|
beta-agonists
|
EFFECT
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s13
|
DDI-DrugBank.d284.s13.p0
|
Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.
|
Paroxetine
|
duloxetine
|
MECHANISM
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s4
|
DDI-DrugBank.d548.s4.p0
|
The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold).
|
estradiol
|
endotoxin
|
MECHANISM
|
7600639.xml
|
DDI-MedLine.d39.s3
|
DDI-MedLine.d39.s3.p0
|
Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
|
Type 1C antiarrhythmics
|
encainide
|
NONE
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s16
|
DDI-DrugBank.d202.s16.p28
|
Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.
|
Lithium
|
diuretics
|
ADVISE
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s5
|
DDI-DrugBank.d231.s5.p0
|
However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
|
quinolones
|
cyclosporine
|
EFFECT
|
Levofloxacin_ddi.xml
|
DDI-DrugBank.d242.s1
|
DDI-DrugBank.d242.s1.p4
|
A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.
|
cimetidine
|
nimodipine
|
MECHANISM
|
Nimodipine_ddi.xml
|
DDI-DrugBank.d310.s3
|
DDI-DrugBank.d310.s3.p2
|
Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
|
blood thinner
|
carbamazepine
|
NONE
|
Fluoxetine_ddi.xml
|
DDI-DrugBank.d482.s14
|
DDI-DrugBank.d482.s14.p4
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
antibiotics
|
thyroid drugs
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p351
|
Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.
|
statins
|
TRACLEER
|
ADVISE
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s29
|
DDI-DrugBank.d289.s29.p0
|
Rifampin: Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
|
rifampin
|
MEPRON
|
MECHANISM
|
Atovaquone_ddi.xml
|
DDI-DrugBank.d424.s3
|
DDI-DrugBank.d424.s3.p3
|
The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
|
fentanyl
|
ketoconazole
|
MECHANISM
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s2
|
DDI-DrugBank.d170.s2.p1
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
Phenothiazines
|
Sparine
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p13
|
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.
|
anticoagulant
|
trichlorfon
|
NONE
|
46730.xml
|
DDI-MedLine.d5.s1
|
DDI-MedLine.d5.s1.p9
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
alcohol
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p1
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
glucocorticoids
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p18
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
astemizole
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p24
|
Cimetidine increased the AUC of epirubicin by 50%.
|
Cimetidine
|
epirubicin
|
MECHANISM
|
Epirubicin_ddi.xml
|
DDI-DrugBank.d428.s10
|
DDI-DrugBank.d428.s10.p0
|
Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.
|
salicylates
|
furosemide
|
EFFECT
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s3
|
DDI-DrugBank.d231.s3.p0
|
Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.
|
vardenafil
|
Vardenafil
|
NONE
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s7
|
DDI-DrugBank.d198.s7.p2
|
Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
|
EQUETROTM
|
felbamate
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s8
|
DDI-DrugBank.d94.s8.p2
|
Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.
|
valproate
|
isoniazid
|
MECHANISM
|
Isoniazid_ddi.xml
|
DDI-DrugBank.d187.s13
|
DDI-DrugBank.d187.s13.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Felbatol
|
morphine
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p481
|
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
|
antipsychotic agents
|
anesthetics
|
EFFECT
|
Haloperidol_ddi.xml
|
DDI-DrugBank.d186.s3
|
DDI-DrugBank.d186.s3.p2
|
Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
|
neomycin
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s6
|
DDI-DrugBank.d450.s6.p17
|
Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
|
Clonidine
|
alcohol
|
EFFECT
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s2
|
DDI-DrugBank.d495.s2.p9
|
If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
|
aluminum hydroxide
|
cimetidine
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s5
|
DDI-DrugBank.d558.s5.p31
|
Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.
|
diflunisal
|
anticoagulants
|
ADVISE
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s2
|
DDI-DrugBank.d132.s2.p0
|
Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine
|
dihydroergotamine
|
ergonovine
|
NONE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s10
|
DDI-DrugBank.d97.s10.p0
|
Doxylamine may enhance the effects of epinephrine.
|
Doxylamine
|
epinephrine
|
EFFECT
|
Doxylamine_ddi.xml
|
DDI-DrugBank.d387.s2
|
DDI-DrugBank.d387.s2.p0
|
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen.
|
caffeine
|
acetaminophen
|
NONE
|
3969689.xml
|
DDI-MedLine.d55.s1
|
DDI-MedLine.d55.s1.p5
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
trimethoprim
|
sulfamethoxazole
|
NONE
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p117
|
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
|
phenothiazines
|
lorazepam
|
NONE
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s1
|
DDI-DrugBank.d18.s1.p25
|
In Study 1, patients with colorectal cancer were given irinotecan/5-FU/leucovorin (bolus-IFL) with or without AVASTIN.
|
irinotecan
|
leucovorin
|
NONE
|
Bevacizumab_ddi.xml
|
DDI-DrugBank.d312.s1
|
DDI-DrugBank.d312.s1.p1
|
It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.
|
fluvoxamine
|
anagrelide
|
MECHANISM
|
Anagrelide_ddi.xml
|
DDI-DrugBank.d75.s10
|
DDI-DrugBank.d75.s10.p0
|
In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
|
non-steroidal anti-inflammatory agent
|
potassium-sparing diuretics
|
EFFECT
|
Amiloride_ddi.xml
|
DDI-DrugBank.d356.s4
|
DDI-DrugBank.d356.s4.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
allopurinol
|
diflunisal
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p121
|
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
|
Anticoagulants
|
ardeparin
|
EFFECT
|
Ardeparin_ddi.xml
|
DDI-DrugBank.d105.s0
|
DDI-DrugBank.d105.s0.p4
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Sporanox
|
Agenerase
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p592
|
Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.
|
terfenadine
|
Itraconazole
|
MECHANISM
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s3
|
DDI-DrugBank.d165.s3.p0
|
There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.
|
loxapine
|
lorazepam
|
EFFECT
|
Loxapine_ddi.xml
|
DDI-DrugBank.d504.s0
|
DDI-DrugBank.d504.s0.p0
|
Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.
|
Quinolones
|
warfarin
|
EFFECT
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s19
|
DDI-DrugBank.d123.s19.p4
|
In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents, folic acid, corticosteroids and/or narcotics.
|
nonsteroidal anti-inflammatory agents
|
folic acid
|
NONE
|
Infliximab_ddi.xml
|
DDI-DrugBank.d45.s4
|
DDI-DrugBank.d45.s4.p4
|
Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
|
Auranofin
|
Depen
|
ADVISE
|
Auranofin_ddi.xml
|
DDI-DrugBank.d374.s1
|
DDI-DrugBank.d374.s1.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
chloral hydrate
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p7
|
If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.
|
iron supplements
|
OMNICEF
|
ADVISE
|
Cefdinir_ddi.xml
|
DDI-DrugBank.d420.s6
|
DDI-DrugBank.d420.s6.p1
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
bupropion
|
imipramine
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p2
|
There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat Pneumocystis carinii pneumonia.
|
TMP
|
SMX
|
NONE
|
Lamivudine_ddi.xml
|
DDI-DrugBank.d71.s3
|
DDI-DrugBank.d71.s3.p2
|
Caution should also be applied for other sympathomimetics, and for aminophylline and theophylline and tricyclic antidepressants, which may also precipitate arrhythmias.
|
sympathomimetics
|
theophylline
|
NONE
|
Halothane_ddi.xml
|
DDI-DrugBank.d74.s4
|
DDI-DrugBank.d74.s4.p1
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
ketoconazole
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p13
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
trimethoprim
|
sulfamethoxazole
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1482
|
Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
|
NSAIDs
|
lithium
|
MECHANISM
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s15
|
DDI-DrugBank.d219.s15.p3
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
|
anesthetic solutions
|
phenothiazines
|
EFFECT
|
Chloroprocaine_ddi.xml
|
DDI-DrugBank.d110.s0
|
DDI-DrugBank.d110.s0.p4
|
Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.
|
quinolones
|
caffeine
|
MECHANISM
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s11
|
DDI-DrugBank.d516.s11.p0
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
carbamazepine
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p5
|
Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
nonsteroidal anti-inflammatory agents
|
Starlix
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s14
|
DDI-DrugBank.d460.s14.p4
|
Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;
|
quinidine
|
flecainide
|
MECHANISM
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s16
|
DDI-DrugBank.d87.s16.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
warfarin
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p42
|
The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.
|
triacetyloleandomycin
|
ergotamine
|
MECHANISM
|
Ergotamine_ddi.xml
|
DDI-DrugBank.d59.s0
|
DDI-DrugBank.d59.s0.p2
|
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.
|
barbiturates
|
carbamazepine
|
NONE
|
Norgestimate_ddi.xml
|
DDI-DrugBank.d360.s1
|
DDI-DrugBank.d360.s1.p2
|
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
|
phenytoin
|
estazolam
|
NONE
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s4
|
DDI-DrugBank.d338.s4.p11
|
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.
|
retinyl acetate
|
insulin
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s2
|
DDI-MedLine.d12.s2.p6
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
sulfamethoxazole
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p13
|
Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.
|
Warfarin
|
anticoagulant
|
NONE
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s24
|
DDI-DrugBank.d516.s24.p1
|
Thus, probenecid should not be administered concurrently with bumetanide.
|
probenecid
|
bumetanide
|
ADVISE
|
Bumetanide_ddi.xml
|
DDI-DrugBank.d331.s6
|
DDI-DrugBank.d331.s6.p0
|
Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
monoamine oxidase inhibitors
|
EFFECT
|
Glipizide_ddi.xml
|
DDI-DrugBank.d225.s0
|
DDI-DrugBank.d225.s0.p7
|
Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
|
sulphonylureas
|
thiazide diuretics
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s35
|
DDI-DrugBank.d558.s35.p41
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;
|
anticoagulant
|
alcohol
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s30
|
DDI-DrugBank.d64.s30.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.